



US005929055A

# United States Patent [19]

[11] Patent Number: **5,929,055**

Ryan et al.

[45] Date of Patent: **Jul. 27, 1999**

[54] **THERAPEUTIC METHOD FOR MANAGEMENT OF DIABETES MELLITUS**

[75] Inventors: **Maria Emanuel Ryan**, Huntington;  
**Lorne M. Golub**; **Nungavaram S. Ramamurthy**, both of Smithtown;  
**Thomas F. McNamara**, Port Jefferson, all of N.Y.

[73] Assignee: **The Research Foundation of State University of New York**, Albany, N.Y.

[21] Appl. No.: **08/880,945**

[22] Filed: **Jun. 23, 1997**

[51] Int. Cl.<sup>6</sup> ..... **A61K 31/65**; A61K 38/28;  
A61K 31/155

[52] U.S. Cl. .... **514/152**; 514/3; 514/634;  
514/866

[58] Field of Search ..... 514/3, 152, 634,  
514/866

[56] **References Cited**

**U.S. PATENT DOCUMENTS**

5,532,227 7/1996 Golub et al. .... 514/152

**FOREIGN PATENT DOCUMENTS**

9513805 5/1995 WIPO .  
9631242 10/1996 WIPO .

**OTHER PUBLICATIONS**

Boyle PJ, Kempers, SF, O'Connor AM and Nagy RJ, "Brain glucose uptake and unawareness of hypoglycemia in patients with insulin-dependent diabetes mellitus," *New England J. Medicine* 333(26):1726-1731 (1995).

Brownlee M, Cerami A, and Vlassara H, "Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications," *Seminars in Medicine of the Beth Israel Hospital, Boston*, 318(20):1315-1321 (1980).

Cerami A, Vlassara H, Brownlee M, "Role of advanced glycosylation products in complications of diabetes," *Diabetes Care*, 11(1):73-79 (1988).

Department of Health and Human Services, Public Health Service, Centers for Disease Control, National Center for Chronic Disease Prevention and Health Promotion, Division of Diabetes Translation, *The Prevention and Treatment of Complication of Diabetes Mellitus: A Guide for Primary Care Practitioners*, (1991) (copy obtained from Centers for Disease Control web site Dec. 4, 1996).

The Diabetes Control and Complications Trial Research Group, "The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus," *New England J. Medicine*, 329(14): 977-986 (1993).

Golub LM, Lee HM, Lehrer G, Nemiroff A, McNamara TF, Kaplan R, and Ramamurthy NS, "Minocycline reduces gingival collagenolytic activity during diabetes," *J. Periodontal Research*, 18:516-526 (1983).

Golub LM, Ramamurthy NS, Kaneko H, Sasaki T, Rifkin B, and McNamara TF, "Tetracycline administration prevents diabetes-induced osteopenia in the rat: initial observations," *Research Communications in Chemical Pathology and Pharmacology*, 68(1):27-40 (1990).

Grossi SG, Skrepcinski FB, DeCaro T, Zambon JJ, Cummins D, and Genco RJ, "Response to periodontal therapy in diabetes and smokers," *J. Periodontol*, 67(10):1094-1102 (1996).

Hamlin CR, Kohn RR, and Luschin JH, "Apparent accelerated aging of human collagen in diabetes mellitus," *Diabetes*, 24(10):902-904 (1975).

Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP and King GL, "Amelioration of vascular dysfunctions in diabetic rats by an oral PKC  $\beta$  inhibitor," *Science*, 272:728-731 (1996).

Lewin DI, "Brain's adaptation to low blood sugar endangers diabetics," *J. NIH Research*, 8:38-39 (1996).

Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A and Vlassara H, "Advanced glycosylation end products in patients with diabetic nephropathy," *New England J. Medicine* 836-842 (1991).

Yu Z, Ramamurthy NS, Leung M, Chang KM, McNamara TF and Golub LM, "Chemically-modified tetracycline normalizes collagen metabolism in diabetic rats: a dose-response study," *J. Periodontal Research*, 28:420-428 (1993).

Porte J Jr and Schwartz MW, "Diabetes complications: Why is glucose potentially toxic?," *Science*, 272:699-700 (1996).

Reiser KM, "Nonenzymatic glycation of collagen in aging and diabetes," *Am J Physiol*, 17-29 (1990).

Schneir M, Ramamurthy N, and Golub L, "Minocycline-treatment of diabetic rats normalizes skin collagen production and mass: possible causative mechanisms," *Matrix*, 10:112-123 (1990).

Windholz et al., *The Merck Index*, 10<sup>th</sup> Ed. (1983) pp. 723 & 724: abstract No. 4866. Insulin.

Primary Examiner—Kevin E. Weddington  
Attorney, Agent, or Firm—Hoffmann & Baron, LLP

[57] **ABSTRACT**

A method for treating diabetes in a mammal by moderately controlling blood glucose concentration in the mammal together with administering to the mammal an amount of a tetracycline compound effective to reduce complications associated with diabetic hyperglycemia. The method enables long term management of diabetes by avoiding the problems associated with tight control of blood glucose concentrations, i.e., hypoglycemia tolerance and seizures, while simultaneously avoiding the problems associated with conventional moderate control of blood glucose concentrations, i.e., pathological complications associated with hyperglycemia, such as nephropathy, retinopathy, etc. Blood glucose concentration can be controlled by moderate administration (e.g., fewer injections per day) of insulin or another glucose-modulating agent, while pathological complications characteristic of diabetic hyperglycemia are ameliorated through the activity of tetracycline compound, the latter preferably administered in an amount that is substantially non-antimicrobial.

**39 Claims, No Drawings**